Effects of Palmitoylethanolamide Combined with Luteoline on Frontal Lobe Functions,High Frequency Oscillations,and GABAergic Transmission in Patients with Frontotemporal Dementia
Restricted accessResearch articleFirst published online August 18, 2020
Effects of Palmitoylethanolamide Combined with Luteoline on Frontal Lobe Functions,High Frequency Oscillations,and GABAergic Transmission in Patients with Frontotemporal Dementia
Frontotemporal dementia (FTD) is a presenile neurodegenerative disease for which there is no effective pharmacological treatment. Recently, a link has been proposed between neuroinflammation and FTD.
Objective:
Here, we aim to investigate the effects of palmitoylethanolamide (PEA) combined with luteoline (PEA-LUT), an endocannabinoid with anti-inflammatory and neuroprotective effects, on behavior, cognition, and cortical activity in a sample of FTD patients.
Methods:
Seventeen patients with a diagnosis of probable FTD were enrolled. Cognitive and neurophysiological evaluations were performed at baseline and after 4 weeks of PEA-LUT 700 mg×2/day. Cognitive effects were assessed by Neuropsychiatric Inventory (NPI), Mini-Mental State Examination, Frontal Assessment Battery (FAB), Screening for Aphasia in Neurodegeneration, Activities of Daily Living-Instrumental Activities of Daily Living, and Frontotemporal Lobar Degeneration-modified Clinical Dementia Rating scale. To investigate in vivo neurophysiological effects of PEA-LUT, we used repetitive and paired-pulse transcranial magnetic stimulation (TMS) protocols assessing LTP-like cortical plasticity, short-interval intracortical inhibition, long-interval intracortical inhibition (LICI), and short-latency afferent inhibition. Moreover, we used TMS combined with EEG to evaluate the effects on frontal lobe cortical oscillatory activity.
Results:
Treatment with PEA-LUT was associated with an improvement in NPI and FAB scores. Neurophysiological evaluation showed a restoration of LICI, in particular at ISI 100 ms, suggesting a modulation of GABA(B) activity. TMS-EEG showed a remarkable increase of TMS-evoked frontal lobe activity and of high-frequency oscillations in the beta/gamma range.
Conclusion:
PEA-LUT could reduce behavioral disturbances and improve frontal lobe functions in FTD patients through the modulation of cortical oscillatory activity and GABA(B)ergic transmission.
ChitramuthuBP, BennettHPJ, BatemanA (2017) Progranulin: A new avenue towards the understanding and treatment of neurodegenerative disease. Brain140, 3081–3104.
SuW-H, ShiZ-H, LiuS-L, WangX-D, LiuS, JiY (2018) The rs75932628 and rs2234253 polymorphisms of the TREM2 gene were associated with susceptibility to frontotemporal lobar degeneration in Caucasian populations. Ann Hum Genet82, 177–185.
CagninA, RossorM, SampsonEL, MacKinnonT, BanatiRB (2004) In vivo detection of microglial activation in frontotemporal dementia. Ann Neurol56, 894–897.
11.
ZhangJ (2015) Mapping neuroinflammation in frontotemporal dementia with molecular PET imaging. J Neuroinflammation12, 108.
12.
ScuderiC, SteccaC, ValenzaM, RatanoP, BronzuoliMR, BartoliS, SteardoL, PompiliE, FumagalliL, CampolongoP, SteardoL (2014) Palmitoylethanolamide controls reactive gliosis and exerts neuroprotective functions in a rat model of Alzheimer’s disease. Cell Death Dis5, e1419.
13.
GuidaF, LuongoL, BoccellaS, GiordanoME, RomanoR, BelliniG, ManzoI, FurianoA, RizzoA, ImperatoreR, IannottiFA, D’AnielloE, PiscitelliF, sca RossiF, CristinoL, Di MarzoV, de NovellisV, MaioneS (2017) Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: Involvement of the CB2 receptor. Sci Rep7, 375.
14.
PalmaE, Reyes-RuizJM, LopergoloD, RosetiC, BertolliniC, RuffoloG, CifelliP, OnestiE, LimatolaC, MilediR, InghilleriM (2016) Acetylcholine receptors from human muscle as pharmacological targets for ALS therapy. Proc Nat. Acad Sci U S A113, 3060–3065.
15.
MusellaA, FresegnaD, RizzoFR, GentileA, BullittaS, De VitoF, GuadalupiL, CentonzeD, MandolesiG (2017) A novel crosstalk within the endocannabinoid system controls GABA transmission in the striatum. Sci Rep7, 7363.
16.
FerrerI (1999) Neurons and their dendrites in frontotemporal dementia. Dement Geriatr Cogn Disord10, 55–60.
17.
BuzsákiG, WangX-J (2012) Mechanisms of gamma oscillations. Annu Rev Neurosci35, 203–225.
18.
Gonzalez-BurgosG, LewisDA (2008) GABA neurons and the mechanisms of network oscillations: Implications for understanding cortical dysfunction in schizophrenia. Schizophr Bull34, 944–961.
19.
HughesLE, RittmanT, RobbinsTW, RoweJB (2018) Reorganization of cortical oscillatory dynamics underlying disinhibition in frontotemporal dementia. Brain141, 2486–2499.
20.
MartoranaA, Di LorenzoF, ManentiG, SempriniR, KochG (2014) Homotaurine induces measurable changes of short latency afferent inhibition in a group of mild cognitive impairment individuals. Front Aging Neurosci6, 254.
21.
KochG, Di LorenzoF, BonnìS, GiacobbeV, BozzaliM, CaltagironeC, MartoranaA (2014) Dopaminergic modulation of cortical plasticity in Alzheimer’s disease patients. Neuropsychopharmacology39, 2654–2661.
MartoranaA, EspositoZ, Di LorenzoF, GiacobbeV, SancesarioGM, BucchiG, BonnìS, BernardiniS, SorgeR, SancesarioG, BernardiG, CaltagironeC, KochG. (2012) Cerebrospinal fluid levels of Aβ42 relationship with cholinergic cortical activity in Alzheimer’s disease patients. J Neural Transm (Vienna)119, 771–778.
25.
CummingsJL, MegaM, GrayK, Rosenberg-ThompsonS, CarusiDA, GornbeinJ (1994) The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology44, 2308–2308.
26.
MagniE, BinettiG, PadovaniA, CappaSF, BianchettiA, TrabucchiM (1996) The Mini-Mental State Examination in Alzheimer’s disease and multi-infarct dementia. Int Psychogeriatr8, 127–134.
27.
AppollonioI, LeoneM, IsellaV, PiamartaF, ConsoliT, VillaML, ForapaniE, RussoA, NichelliP (2005) The Frontal Assessment Battery (FAB): Normative values in an Italian population sample. Neurol Sci26, 108–116.
28.
CatricalàE, GobbiE, BattistaP, MiozzoA, PolitoC, BoschiV, EspositoV, CuocoS, BaroneP, SorbiS, CappaSF, GarrardP (2017) SAND: A Screening for Aphasia in NeuroDegeneration. Development and normative data. Neurol Sci38, 1469–1483.
29.
GalaskoD, SchmittF, ThomasR, JinS, BennettD, FerrisS (2005) Detailed assessment of activities of daily living in moderate to severe Alzheimer’s disease. J Int Neuropsychol Soc11, 446–453.
30.
BorroniB, AgostiC, PremiE, CeriniC, CossedduM, PagheraB, BellelliG, PadovaniA (2010) The FTLD-modified Clinical Dementia Rating scale is a reliable tool for defining disease severity in Frontotemporal Lobar Degeneration: Evidence from a brain SPECT study: Usefulness of FTLD-modified CDR. Eur J Neurol17, 703–707.
31.
RossiniPM, BarkerAT, BerardelliA, CaramiaMD, CarusoG, CraccoRQ, DimitrijevićMR, HallettM, KatayamaY, LückingCH, Maertens de NoordhoutAL, MarsdenCD, MurrayNMF, RothwellJC, SwashM, TombergC (1994) Non-invasive electrical and magnetic stimulation of the brain, spinal cord and roots: Basic principles and procedures for routine clinical application. Report of an IFCN committee. Electroencephalogr Clin Neurophysiol91, 79–92.
32.
RothwellJC (1997) Techniques and mechanisms of action of transcranial stimulation of the human motor cortex. J Neurosci Methods74, 113–122.
33.
KujiraiT, CaramiaMD, RothwellJC, DayBL, ThompsonPD, FerbertA, WroeS, AsselmanP, MarsdenCD (1993) Corticocortical inhibition in human motor cortex. J Physiol471, 501–519.
34.
RocchiL, ErroR, AntelmiE, BerardelliA, TinazziM, LiguoriR, BhatiaK, RothwellJ (2017) High frequency somatosensory stimulation increases sensori-motor inhibition and leads to perceptual improvement in healthy subjects. Clin Neurophysiol128, 1015–1025.
35.
Valls-SoléJ, Pascual-LeoneA, WassermannEM, HallettM (1992) Human motor evoked responses to paired transcranial magnetic stimuli. Electroencephalogr Clin Neurophysiol Potentials Sect85, 355–364.
36.
HuangY-Z, EdwardsMJ, RounisE, BhatiaKP, RothwellJC (2005) Theta burst stimulation of the human motor cortex. Neuron45, 201–206.
37.
MassiminiM (2005) Breakdown of cortical effective connectivity during sleep. Science309, 2228–2232.
38.
CasulaEP, BertoldoA, TarantinoV, MaiellaM, KochG, RothwellJC, ToffoloGM, BisiacchiPS (2017) TMS-evoked long-lasting artefacts: A new adaptive algorithm for EEG signal correction. Clin Neurophysiol128, 1563–1574.
39.
LehmannD, SkrandiesW (1980) Reference-free identification of components of checkerboard-evoked multichannel potential fields. Electroencephalogr Clin Neurophysiol48, 609–621.
40.
CasulaEP, RocchiL, HannahR, RothwellJC (2018) Effects of pulse width, waveform and current direction in the cortex: A combined cTMS-EEG study. Brain Stimulat11, 1063–1070.
41.
KochG (2019) The new era of TMS-EEG: Moving towards the clinical practice. Clin Neurophysiol130, 791–792.
42.
RosanovaM, CasaliA, BellinaV, RestaF, MariottiM, MassiminiM (2009) Natural frequencies of human corticothalamic circuits. J Neurosci29, 7679–7685.
43.
CasulaEP, MaiellaM, PellicciariMC, PorrazziniF, D’AcuntoA, RocchiL, KochG (2020) Novel TMS-EEG indexes to investigate interhemispheric dynamics in humans. Clin Neurophysiol131, 70–77.
44.
PerryRJ, MillerBL (2001) Behavior and treatment in frontotemporal dementia. Neurology56, S46–S51.
45.
ChowTW, MendezMF (2002) Goals in symptomatic pharmacologic management of frontotemporal lobar degeneration. Am J Alzheimers Dis Other Demen17, 267–272.
46.
FellgiebelA, MüllerMJ, HiemkeC, BartensteinP, SchreckenbergerM (2007) Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism. World J Biol Psychiatry8, 123–126.
47.
HueyED, GarciaC, WassermannEM, TiernyMC, GrafmanJ (2008) Stimulant treatment of frontotemporal dementia in 8 patients. J Clin Psychiatry69, 1981–1982.
48.
ReevesRR, PerryCL (2013) Aripiprazole for sexually inappropriate vocalizations in frontotemporal dementia. J Clin Psychopharmacol33, 3.
49.
PijnenburgYAL, SampsonEL, HarveyRJ, FoxNC, RossorMN (2003) Vulnerability to neuroleptic side effects in frontotemporal lobar degeneration. Int J Geriatr Psychiatry18, 67–72.
LebertF, StekkeW, HasenbroekxC, PasquierF (2004) Frontotemporal dementia: A randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord17, 355–359.
52.
MorettiR, TorreP, AntonelloRM, CazzatoG, BavaA (2003) Frontotemporal dementia: Paroxetine as a possible treatment of behavior symptoms. Eur Neurol49, 13–19.
53.
ProdanCI, MonnotM, RossED (2009) Behavioural abnormalities associated with rapid deterioration of language functions in semantic dementia respond to sertraline. J Neurol Neurosurg Psychiatry80, 1416–1417.
54.
BenussiA, GrassiM, PalluzziF, KochG, Di LazzaroV, NardoneR, CantoniV, Dell’EraV, PremiE, MartoranaA, LorenzoF, BonnìS, RanieriF, CaponeF, MusumeciG, CotelliMS, PadovaniA, BorroniB (2020) Classification accuracy of transcranial magnetic stimulation for the diagnosis of neurodegenerative dementias. Ann Neurol87, 394–404.
55.
BenussiA, Di LorenzoF, Dell’EraV, CossedduM, AlbericiA, CaratozzoloS, CotelliMS, MicheliA, RozziniL, DepariA, FlamminiA, PonzoV, MartoranaA, CaltagironeC, PadovaniA, KochG, BorroniB (2017) Transcranial magnetic stimulation distinguishes Alzheimer disease from frontotemporal dementia. Neurology89, 665–672.
56.
TokimuraH, Di LazzaroV, TokimuraY, OlivieroA, ProficeP, InsolaA, MazzoneP, TonaliP, RothwellJC (2000) Short latency inhibition of human hand motor cortex by somatosensory input from the hand. J Physiol523, 503–513.
57.
ZiemannU, RothwellJC, RiddingMC (1996) Interaction between intracortical inhibition and facilitation in human motor cortex. J Physiol496, 873–881.
58.
CasulaEP, PellicciariMC, PonzoV, Stampanoni BassiM, VenieroD, CaltagironeC, KochG (2016) Cerebellar theta burst stimulation modulates the neural activity of interconnected parietal and motor areas. Sci Rep6, 36191.
59.
CasulaEP, TarantinoV, BassoD, ArcaraG, MarinoG, ToffoloGM, RothwellJC, BisiacchiPS (2014) Low-frequency rTMS inhibitory effects in the primary motor cortex: Insights from TMS-evoked potentials. Neuroimage98, 225–232.
60.
PremoliI, CastellanosN, RivoltaD, BelardinelliP, BajoR, ZipserC, EspenhahnS, HeideggerT, Muller-DahlhausF, ZiemannU (2014) TMS-EEG signatures of GABAergic neurotransmission in the human cortex. J Neurosci34, 5603–5612.
HowardMW (2003) Gamma oscillations correlate with working memory load in humans. Cereb Cortex13, 1369–1374.
63.
UhlhaasPJ, PipaG, LimaB, MelloniL, NeuenschwanderS, NikolićD, SingerW (2009) Neural synchrony in cortical networks: History, concept and current status. Front Integr Neurosci3, 17.
64.
PerryRJ, HodgesJR (2000) Differentiating frontal and temporal variant frontotemporal dementia from Alzheimer’s disease. Neurology54, 2277–2284.
65.
StopfordCL, ThompsonJC, NearyD, RichardsonAMT, SnowdenJS (2012) Working memory, attention, and executive function in Alzheimer’s disease and frontotemporal dementia. Cortex48, 429–446.
UhlhaasPJ, SingerW (2010) Abnormal neural oscillations and synchrony in schizophrenia. Nat Rev Neurosci11, 100–113.
68.
CooperJJ, OvsiewF (2013) The relationship between schizophrenia and frontotemporal dementia. J Geriatr Psychiatry Neurol26, 131–137.
69.
IannottiFA, Di MarzoV, PetrosinoS (2016) Endocannabinoids and endocannabinoid-related mediators: Targets, metabolism and role in neurological disorders. Prog Lipid Res62, 107–128.
70.
PetrosinoS, Di MarzoV (2017) The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations: Palmitoylethanolamide and its new formulations. Br J Pharmacol174, 1349–1365.
71.
TsuboiK, UyamaT, OkamotoY, UedaN (2018) Endocannabinoids and related N-acylethanolamines: Biological activities and metabolism. Inflamm Regen38, 28.
72.
Lo VermeJ, FuJ, AstaritaG, La RanaG, RussoR, CalignanoA, PiomelliD (2005) The nuclear receptor peroxisome proliferator-activated receptor-α mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol67, 15–19.
73.
PertweeRG (2009) GPR55: A new member of the cannabinoid receptor clan? Commentary. Br J Pharmacol152, 984–986.
74.
DevchandPR, KellerH, PetersJM, VazquezM, GonzalezFJ, WahliW (1996) The PPAR alpha-leukotriene B4 pathway to inflammation control. Nature384, 39–43.
75.
StrausDS, GlassCK (2007) Anti-inflammatory actions of PPAR ligands: New insights on cellular and molecular mechanisms. Trends Immunol28, 551–558.
76.
BeggiatoS, TomasiniMC, FerraroL (2019) Palmitoylethanolamide (PEA) as a potential therapeutic agent in Alzheimer’s disease. Front Pharmacol10, 821.
77.
Mattace RasoG, RussoR, CalignanoA, MeliR (2014) Palmitoylethanolamide in CNS health and disease. Pharmacol Res86, 32–41.
78.
PetrosinoS, Schiano MorielloA, CerratoS, FuscoM, PuigdemontA, De PetrocellisL, Di MarzoV (2016) The anti-inflammatory mediator palmitoylethanolamide enhances the levels of 2-arachidonoyl-glycerol and potentiates its actions at TRPV1 cation channels: Novel palmitoylethanolamide ‘entourage effects.’. Br J Pharmacol173, 1154–1162.
79.
ZygmuntPM, ErmundA, MovahedP, AnderssonDA, SimonsenC, JönssonBAG, BlomgrenA, BirnirB, BevanS, EschalierA, MalletC, GomisA, HögestättED (2013) Monoacylglycerols activate TRPV1 – a link between phospholipase C and TRPV1. PLoS One8, e81618.
80.
SeelaarH, RohrerJD, PijnenburgYAL, FoxNC, van SwietenJC (2011) Clinical, genetic and pathological heterogeneity of frontotemporal dementia: A review. J Neurol Neurosurg Psychiatry82, 476–486.
81.
WhitwellJL, PrzybelskiSA, WeigandSD, IvnikRJ, VemuriP, GunterJL, SenjemML, ShiungMM, BoeveBF, KnopmanDS, ParisiJE, DicksonDW, PetersenRC, JackCR, JosephsKA (2009) Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: A cluster analysis study. Brain132, 2932–2946.
82.
JichaGA, NelsonPT (2011) Management of frontotemporal dementia: Targeting symptom management in such a heterogeneous disease requires a wide range of therapeutic options. Neurodegener Dis Manag1, 141–156.
